

#### **REVISIONE MRI PROSTATICA**

**Sarah Alessi** 






IEO
European Institute of Oncology


Research for care

### S.S. comes to IEO

- 70 years
  - Lawyer
  - PSA increasing; PSA= 14ng/ml ratio 31% PHI 84
  - September 2016 Bx (12 regions) negative
  - mp-MRI (peripheral center): PI-RADS 5 right base postero-lateral.

# Peripheral mp-MRI









Peripheral: PI-RADS 5 right base

## **MDT**

- Revision mp-MRI: negative
  - Follow-up
  - PSA
  - mp-MRI in our Institute after 6 months.

# IEO mp-MRI








PI-RADS 2; central zone TZ right base

## **MDT**

- Elevated PSA
- IEO saturation biopsy
  - negative; basal cells hyperplasia and fibrosis.



## Experience is maximized in MDT

 266 outside mpMRIs reviewed by two 'specialist radiologists' (8 & 5 yrs experience) <sup>1</sup>

## Aims of the study

- Inter-reader agreement between radiologists
  - Inexperienced (peripheral centers) vs. Experienced (Academic centers)


- Rate of management strategy changes
  - Targeted biopsies skipped
  - Overall biopsies avoided



# Results: primary endpoint

Index lesion PI-RADS score

Fair (k=0.23; 95% CI: 0.17-0.3) agreement



Central review:

Reduces PI-RADS 3-4 lesions


Increases PI-RADS 1-2

<sup>1</sup>Luzzago et al Clinical Genitourinary Cancer 2018

### T.R. comes to our IEO


- 54 years
  - PSA = 5.2 ng/ml
  - mp-MRI (peripheral center) : PI-RADS 4; 8mm
     right postero-lateral apex
  - Random biopsy: negative

## Peripheral mp-MRI




Central review: PI-RADS 2 PZ right and left No target biopsy

## IEO mp-MRI after 6 months



Lesion	Size	Site	Level	Dist. Apex	T2W	DW	DCE	ADC	SD	Contact with Capsule	Position	ECE	PI-RADS
11	diffuse alteration	PZ - dx;sn	Intermediate; Apex	mm	2	2	0	1055	19	YES	laterale dx;laterale sn;postero-laterale dx;postero-laterale sn	1	2

# IEO mp-MRI after 6 months




PI-RADS 2 PZ right and left mid and apex

# Results: primary endpoint

#### **Clinical Management**

Fair (k=0.21; 95% CI: 0.1-0.28) agreement




- Management changes in 48%
- 52% fewer targeted biopsies
- 33.5% overall biopsies skipped


#### B.A. comes to IEO

- 63 years
  - $PSA = 9,01 \, ng/ml$
  - PCa GS 3+3 2/12 right 20%-10%; left neg.
  - mp-MRI (peripheral center): PI-RADS 3/4 12mm rt PZ intermediate postero-lateral
  - -cT1c
  - Low risk NCCN 2016 → active surveillance?
  - Clinical question: target biopsy?

## **MDT**

mp-MRI revision







PI-RADS 5 15mm TZ right base and intermediate

RARP → GS 4+3 pT3a

«... the inappropriate use of PI-RADS v2 by new users, who do not have sufficient training or experience may be damaging to clinical care»<sup>1</sup>

 Interreader reproducibility tended to be higher for relatively experienced readers than for less experienced readers and to be higher in the PZ than in the TZ

- Priority should be given to development of programs to provide dedicated training and specialty-level expertise in prostate MRI interpretation.
  - .. Rosenkrantz et al, AJR 2016.

## Learning curve





Fig. 3—Learning curves in prostate MRI interpretation for readers without (solid blue line) and with (dashed red line) continual case-based feedback. Proportion of examinations correctly interpreted by readers without (blue data points) and with (red data points) feedback was plotted for consecutive sets of four examinations, and learning curves were fit using locally weighted scatterplot smoothing.



B Finding: Within the right anterior PZ and TZ is a large region of markedly decreased ADC and increased high b-value signal, with associated focal early enhancement and locally invasive behavior.

61 year-old man with PSA of 21.8


Select Scroll, Zoom/Pan, and Window/Level to perform each of these functions. Scroll and zoom using the middle mouse button or mouse wheel. Pan and window/level using the left mouse button.

ng/mL. Prior negative biopsy.

PREVIOUS

T2WI: 5. DWI: 5. DCE: (+). PI-RADS: 5.

MRI/TRUS fusion biopsy: Gleason score 4+3 tumor.



- 1. Rosenkrantz et al, AJR 2017.
- 2. Rosenkrantz et al, Current Problems in Diagnostic Radiology 2019.

## Who is the 'specialist radiologist'?

- Specialist radiologist > 2000 mpMRIs
- General radiologist → 300-500 mpMRIs

ORIGINAL RESEARCH


# Accuracy and Agreement of PIRADSv2 for Prostate Cancer mpMRI: A Multireader Study

Matthew D. Greer BS,<sup>1,2</sup> Anna M. Brown BSE, MPhil,<sup>1,3</sup> Joanna H. Shih PhD,<sup>4</sup> Ronald M. Summers MD, PhD,<sup>5</sup> Jamie Marko MD,<sup>6</sup> Yan Mee Law MD,<sup>7</sup> Sandeep Sankineni MD,<sup>1</sup> Arvin K. George MD,<sup>8</sup> Maria J. Merino MD,<sup>9</sup> Peter A. Pinto MD,<sup>8</sup> Peter L. Choyke MD,<sup>1</sup> and Baris Turkbey MD<sup>1</sup>\*


## Clinical case: Quality check

- 66yo
  - PSA = 4,39 ng/mL
  - GS 3+3 left 1/12
  - cT1c

- MRI outside Institution
  - PI-RADS 3 (PZ left , mid)
  - Not multiparametric!
    - No ADC
    - No DCE



## Clinical case



## Optimising mp-MRI: prepare for success

- PI-RADS v2.1 recommendations (2019)
- Hardware, software, scanning parameters
- Patient-related factors: bowel peristalsis, rectal distension, total hip replacement, post-biopsy haemorrhage

## Experienced MDT -> adapts to clinical context

#### Patient group clinical priorities

#### First biopsy

- -Detect all csPCa
- -Do not over-diagnose insignPCa

#### Repeat biopsy

- Do not miss csPCa

#### mp-MRI Reading strategy

- Maximise SPecificity
- SEnsitivity adjustments to clinical data (PSAD, F/H, risk calculator)

- Maximise SEnsitivity
- Review blind spots (TZ, AFMS, CZ, subcapsular regions)

## Key messages

MDT increase value with few biopsies and improved decisions on biopsy methods

Reviews should take into account the risk of csPCa depending on clinical factors

 Reading of images should also be weighted according to clinical priorities (SEnsitivity or SPecificity)



## THANK YOU

Prostate MRI Team (IEO)

G. Petralia, MD, S. Alessi, MD, P. Pricolo, MD, P. Summers, PhD